656-06-4

Usage

Uses

Used in Organic Synthesis:
3-Amino-4-(trifluoromethoxy)benzoic acid is utilized as a building block in organic synthesis, providing a versatile starting material for the creation of more complex organic molecules. Its unique structure allows for various chemical reactions, facilitating the synthesis of a wide range of compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3-Amino-4-(trifluoromethoxy)benzoic acid serves as a valuable component in drug discovery and development. Its distinct chemical features make it a promising candidate for the design and synthesis of new drugs with potential therapeutic benefits.
Used in Drug Development:
Due to its unique chemical structure, 3-Amino-4-(trifluoromethoxy)benzoic acid may have potential applications in the development of innovative drugs or materials. Researchers can explore its properties to create novel therapeutic agents with improved efficacy and selectivity.
Used in Biological Activity Studies:
3-Amino-4-(trifluoromethoxy)benzoic acid may possess biological activity, warranting investigation into its potential therapeutic properties. Further research could reveal its interactions with biological systems and its capacity to modulate specific biological pathways, offering new avenues for treatment and intervention in various diseases.

Upstream product

• 784-77-0 3-nitro-4-(trifluoromethoxy)benzoic acid 

Downstream Products

• 85373-96-2 3-bromo-4-(trifluoromethoxy)benzoic acid 
• 1027354-87-5 4-[1-[3-amino-4-(trifluoromethoxy)benzoyl]-4-piperidyl]benzonitrile 

Relevant academic research and scientific papers

BISAMLDE DERIVATIVES AND USE THEREOF AS FATTY ACID SYNTHASE INHIBITORS

A compound of formula I, or a pharmaceutically acceptable salt thereof, processes for preparing such compounds, their use as Fatty Acid Synthase inhibitors, methods for their therapeutic use, particularly in the treatment of obesity and diabetes mellitus,

PIPERIDINE DERIVATIVES FOR THE TREATMENT OF OBESITY

A compound of formula (I) or a pharmaceutically acceptable salt thereof, processes for preparing such compounds, their use as Fatty Acid Synthase inhibitors, methods for their therapeutic use, particularly in the treatment of obesity, diabetes mellitus, c

PIPERIDINE DERIVATIVES FOR THE TREATMENT OF OBESITY

A compound of formula (I), or a pharmaceutically acceptable salt thereof, processes for preparing such compounds, their use as Fatty Acid Synthase inhibitors, methods for their therapeutic use, particularly in the treatment of obesity and diabetes mellitu

BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C

A compound which is a biphenyl derivative of formula (I), or a pharmaceutically acceptable salt thereof wherein: R1 is a C1-C6 alkyl group or a moiety -A1, -L1-A1, -A1-A1′, -L1-A1-A1′, -A1-L1-A1′, -A1-Y1-A1′, -A1-Het1-A1′, -L1-A1-Y1-A1′, -L1-A1-Het1-A1′, -L1-Het1-A1, -L1-Y1-A1, -L1-Y1-Het1-A1, -L1-Het1-Y1-A1, -L1-Y1-Het1-L1′, -A1-Y1-Het1-A1′, -A1-Het1-Y1-A1′, -A1-Het1-L1-A1′, -A1-L1-Het1-A1′ or -L1-Het1-L1′; - A and B are the same or different and each represent a direct bond or a -CO- NR′-, -NR′-CO-, -NR′-CO2-, -CO-, -NR′-CO-NR′′-, -NR′-S(O)2-, -S(O)2-NR′-, -SO2-, -NR′-, -NR′-CO-CO-, -CO-O-, -O-CO-, -(C1-C2 alkylene)-NR′- or -(C1-C2 hydroxyalkylene)-NR′ - moiety, wherein R′ and R′′ are the same or different and each represent hydrogen or C1-C4 alkyl; - R2 and R3 are the same or different and each represent C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy or halogen; n and m are the same or different and each represent 0 or 1 ; R4 is a C1-C6 alkyl group or a moiety -A4, -L4-A4, -A4-A4′, -L4-A4-A4′ , -A4-L4-A4′, -A4-Y4-A4′, -A4-Het4-A4′, -L4-A4-Y4-A4′, -L4-A4-Het4-A4′, -L4-Het4-A4, -L4-Y4-A4, -L4-Y4-Het4-A4, -L4-Het4-Y4-A4, -L4-Y4-Het4-L4′, -A4-Y4-Het4-A4′, -A4-Het4-Y4-A4′, -A4-Het4-L4-A4′, -A4-L4-Het4-A4′ or -L4-Het4-L4′, each A1, A4, A1′ and A4′ are the same or different and represent a phenyl, 5- to 10- membered heteroaryl, 5- to 10- membered heterocyclyl or C3-C8 carbocyclyl moiety; each L1 and L4 is the same or different and represents a C1-C4 alkylene or a C1-C4 hydroxyalkylene group; each Y1 and Y4 is the same or different and represents -CO-, -SO- or -S(O)2-; each L1′ and L4′ is the same or different and represents hydrogen or a C1-C4 alkyl group; and each Het1 and Het4 is the same or different and represents -O-, -S- or -NR′-, wherein R′ is hydrogen or a C1-C4 alkyl group, the phenyl, heteroaryl, heterocyclyl and carbocyclyl moieties in R1 and R4 being optionally fused to a phenyl, 5- to 10- membered heteroaryl or 5- to 10- membered heterocyclyl ring; and the phenyl, heteroaryl, heterocyclyl and carbocyclyl moieties in R1 and R4 being unsubstituted or substituted by (a) a single unsubstituted substituent selected from -(C1-C4 alkyl)-X1, -CO2R′, -SO2NR′R′′, -S(O)2-R′, -CONR′R′′, -NR′-CO-R′′′, -NR′-S(O)2-R′′′, -CO-NR′-(C1-C4 alkyl)-NR′R′′ and -CO-O-(C1-C4 alkyl)-NR′R′′ and/or (b) 1, 2 or 3 unsubstituted substituents selected from -(C1-C4 alkyl)-X2, halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 hydroxyalkyl, hydroxy, cyano, nitro and -NR′R′′, wherein X1 is -CO2R′, -SO2-R′, -NR′-CO2-R′′, -NR′-S(O)2-R′′′, -CONR′R′′ or -SO2-NR′R′′, each X2 is the same or different and is cyano, nitro or -NR′R′′, each R′ and R′′ is the same or different and represents hydrogen or C1-C4 alkyl and each R′′′ is the same or different and represents C1-C4 alkyl.